The Company’s Board of Directors resolved to issue 2026 employee stock options and the subscription rules

The Company’s BOD resolved to forfeit the subscription of OBIGEN Pharma’s cash capital increase and distribute the rights to its shareholders

Announcement of the Company’s new appointment of financial and corporate governance officer

Announcement of the Company’s new appointment of acting spokesperson

Announcement of the Consolidated Financial Statements for the second quarter of 2026 were approved by the Board of Directors

Announcement of Changes in the Company’s COO, Financial Officer, Corporate Governance Officer, and Acting Spokesperson

Announcement for the expected date of the Board of Directors Meeting for 2026Q2 consolidated financial report is 2026/08/12

Announcement of changes to members of the Company’s Sustainable Development Committee

Announcement of 2026 Annual General Shareholders' meeting’s resolution to lift the non-competition restrictions for directors

Announcement of the Company’s important resolutions of the 2026 Annual General Shareholders’ meeting.